<DOC>
	<DOCNO>NCT00350623</DOCNO>
	<brief_summary>This study test safety immunogenicity investigational Human Immunodeficiency Virus ( HIV ) vaccine . Immunogenicity measure evaluate immune response several different dose level .</brief_summary>
	<brief_title>Investigation V520 HIV Vaccine Dose Refinement Study ( V520-027 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Demonstrates good general health Human Immunodeficiency Virus ( HIV ) , Hepatitis B surface Antigen ( HBsAg ) , Hepatitis C ( HCV ) seronegative Low risk acquire HIV infection ALT lab value within normal range Previously receive investigational HIV vaccine Has know suspect impairment immunologic function Has clinically significant chronic medical condition consider progressive Has major psychiatric illness Has history malignancy , exception basal cell squamous cell skin cancer Weighs le 105 lb . Has recent ( within two year ) history chronic alcohol abuse Has contraindication intramuscular ( IM ) injection , anticoagulant therapy thrombocytopenia Female pregnant breast feeding , expect conceive donate egg study Male subject plan impregnate provide sperm donation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>AIDS</keyword>
</DOC>